Does Bangladesh Bican Pharmaceuticals have generic versions of Brigatinib/Brigatinib?

Brigatinib/Brigatinib inhibits the activity of ALK fusion protein and blocks the activation of abnormal signaling pathways, thereby inhibiting the growth and spread of tumor cells. ALKfusion protein is an abnormal protein produced by the fusion of the ALK gene with other genes. It is more common in NSCLC patients. By inhibiting this specific molecular target, brigatinib can interfere with the survival and proliferation of tumor cells, thereby inhibiting tumor progression.

Bangladesh Bican Pharmaceuticals Currently there is no generic drug of Brigatinib/(Brigatinib). There are generic drugs of Yaopin International. Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.

Brigatinib/Brigatinib has shown significant efficacy in the treatment of ALK-positive NSCLC patients. It is approved for first-line and second-line treatment, and can prolong the progression-free survival and overall survival of patients and reduce the risk of tumor progression. However, each patient's situation is unique and treatment options should be individualized based on the patient's specific circumstances.

Brigatinib/BrigatinibIt is an oral medication and is available in tablet form. The generally recommended dose is to take it by mouth once daily with a meal. Specific dosage adjustments and treatment regimens should be individualized based on the patient's condition and physician's recommendations.